Wolverine Asset Management’s Cytokinetics CYTK Stock Holding History

Wolverine Asset Management’s Portfolio CYTK Stock Details CYTK Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-5,000	Closed	-$318K	–	1751
2025 Q4	$318K	Hold	5,000	–	–	﹤0.01%	1034
2025 Q3	$275K	Hold	5,000	–	–	﹤0.01%	963
2025 Q2	$165K	Hold	5,000	–	–	﹤0.01%	1053
2025 Q1	$201K	Hold	5,000	–	–	﹤0.01%	1006
2024 Q4	$235K	Sell	5,000 -4,400	-47%	-$229K	﹤0.01%	1000
2024 Q3	$496K	Hold	9,400	–	–	0.01%	864
2024 Q2	$509K	Sell	9,400 -17,100	-65%	-$1.03M	0.01%	836
2024 Q1	$1.86M	Sell	26,500 -48,200	-65%	-$3.73M	0.02%	512
2023 Q4	$6.24M	Buy	74,700 +18,700	+33%	+$677K	0.05%	307
2023 Q3	$1.65M	Hold	56,000	–	–	0.02%	585
2023 Q2	$1.83M	Buy	56,000 +18,900	+51%	+$699K	0.02%	529
2023 Q1	$1.31M	Sell	37,100 -40,700	-52%	-$1.66M	0.02%	619
2022 Q4	$3.56M	Buy	77,800 +51,700	+198%	+$2.22M	0.04%	425
2022 Q3	$1.26M	Buy	+26,100	New	+$1.26M	0.01%	708

Other funds holding CYTK

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Wolverine Asset Management's CYTK Position: Q2 2026 in Review

Wolverine Asset Management sold out of Cytokinetics (CYTK) in Q2 2026, closing a stake of 120 shares — an estimated $7.91K sold.

Wolverine Asset Management first reported a position in CYTK in Q4 2025 and held it in 2 quarters. The position peaked at $349K in Q4 2025. 482 funds tracked by Wall St. Rank hold CYTK as of Q2 2026.

Wolverine Asset Management reported no remaining Cytokinetics position as of Q2 2026 after selling out during the quarter.
Wolverine Asset Management sold 120 Cytokinetics shares in Q2 2026, an estimated $7.91K.
Wolverine Asset Management first reported a position in Cytokinetics in Q4 2025 and held it in 2 quarters.
Wolverine Asset Management's Cytokinetics position peaked at $349K in Q4 2025.
482 funds tracked by Wall St. Rank held Cytokinetics as of Q2 2026.

Based on Wolverine Asset Management's 13F filing for Q2 2026, filed 10 Aug 2026.